Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actavis’ Launch Of Pulmicort Respules Generic Halted By Court

This article was originally published in The Pink Sheet Daily

Executive Summary

One day after declaring one Pulmicort patent invalid and another not infringed, a New Jersey federal judge granted AstraZeneca’s bid to temporarily block Actavis and other ANDA filers from launching and distributing their budesonide generics.

You may also be interested in...



Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages

Teva and India’s Sun Pharma are to pay $2.15 billion for their at-risk launch in the U.S. of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.

Protonix Settlement Leaves Question Of How Jury Would Assess At-Risk Launch Damages

Teva and Sun are to pay $2.15 billion for their at-risk launch of generic versions of Pfizer’s Protonix; Pfizer says figure represents lost profits and lost royalties from the three years the product faced premature generic competition.

Actavis’ Pulmicort Respules Generics Race Out The Door Before “Short Injunction”

The company is barred from further distributing its budesonide inhalation suspension until April 12; the generic launched April 1 following a patent victory over AstraZeneca, but a New Jersey federal judge said a “limited temporary injunction” was warranted to give the innovator time to seek appellate relief.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel